-+ 0.00%
-+ 0.00%
-+ 0.00%

AC Immune Phase 1 data show higher ACI-19626 TDP-43 PET uptake in ALS brains

PUBT·05/22/2026 11:00:40
Listen to the news
AC Immune Phase 1 data show higher ACI-19626 TDP-43 PET uptake in ALS brains
  • AC Immune presented new preliminary Phase 1 data at the 2026 TDP43 Summit indicating its TDP-43 PET tracer ACI-19626 showed higher brain uptake in patients with amyotrophic lateral sclerosis than in healthy controls.
  • The readout supports the tracer’s potential to detect TDP-43 pathology in living patients, a step that could strengthen earlier diagnosis strategies for ALS and other TDP-43 proteinopathies.
  • The company reported the program continued to show a favorable safety and tolerability profile, supporting further clinical work.
  • The first-in-human Phase 1 study has completed an initial segment in healthy volunteers and genetic frontotemporal dementia, with an expansion underway that can enroll up to 30 patients across frontotemporal dementia, ALS, or LATE.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605220700PRIMZONEFULLFEED1001183473) on May 22, 2026, and is solely responsible for the information contained therein.